- Home
- FMAO vs AVIR Comparison
FMAO vs AVIR Comparison
Compare FMAO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- AVIR
- Stock Information
- Founded
- FMAO 1897
- AVIR 2012
- Country
- FMAO United States
- AVIR United States
- Employees
- FMAO N/A
- AVIR N/A
- Industry
- FMAO Savings Institutions
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- FMAO Finance
- AVIR Health Care
- Exchange
- FMAO Nasdaq
- AVIR Nasdaq
- Market Cap
- FMAO 359.3M
- AVIR 290.4M
- IPO Year
- FMAO N/A
- AVIR 2020
- Fundamental
- Price
- FMAO $25.81
- AVIR $2.91
- Analyst Decision
- FMAO
- AVIR Hold
- Analyst Count
- FMAO 0
- AVIR 1
- Target Price
- FMAO N/A
- AVIR $6.00
- AVG Volume (30 Days)
- FMAO 15.0K
- AVIR 217.7K
- Earning Date
- FMAO 10-29-2025
- AVIR 11-06-2025
- Dividend Yield
- FMAO 3.36%
- AVIR N/A
- EPS Growth
- FMAO 38.39
- AVIR N/A
- EPS
- FMAO 2.16
- AVIR N/A
- Revenue
- FMAO $108,632,000.00
- AVIR N/A
- Revenue This Year
- FMAO $1.60
- AVIR N/A
- Revenue Next Year
- FMAO $13.77
- AVIR N/A
- P/E Ratio
- FMAO $12.20
- AVIR N/A
- Revenue Growth
- FMAO 13.86
- AVIR N/A
- 52 Week Low
- FMAO $20.88
- AVIR $2.46
- 52 Week High
- FMAO $34.15
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- FMAO 49.80
- AVIR 29.44
- Support Level
- FMAO $25.08
- AVIR $3.10
- Resistance Level
- FMAO $26.50
- AVIR $3.33
- Average True Range (ATR)
- FMAO 0.81
- AVIR 0.14
- MACD
- FMAO -0.08
- AVIR -0.05
- Stochastic Oscillator
- FMAO 35.68
- AVIR 7.69
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).